clonoSEQ MRD Test Featured in 89 Abstracts at ASH 2025—Expanding Role in Blood Cancer Care

ASH 2025: clonoSEQ Presence Highlights Growing Impact on Treatment Decisions

Adaptive Biotechnologies' clonoSEQ minimal residual disease (MRD) test will be featured in a remarkable 89 abstracts—including 36 oral presentations—at the upcoming 67th Annual Meeting of the American Society of Hematology (ASH) in December 2025. This broad scientific engagement not only underscores the clinical relevance of clonoSEQ but also signals its expanding utility across various hematologic malignancies.

Multi-Cancer Adoption: From Multiple Myeloma to Lymphoma

Researchers at ASH 2025 will showcase clonoSEQ data spanning multiple myeloma (MM), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and other blood cancers. clonoSEQ’s footprint across this diverse set of lymphoid cancers reflects its position as the most widely used and validated next-generation sequencing (NGS)-based MRD assay in the field.

Table: Distribution of clonoSEQ Abstracts by Cancer Type

Note: Rounded estimates based on abstract summary; full breakdown available on request.

MRD Testing Is Shaping Real-World Treatment Choices

Over 17 presentations at ASH will explore how clonoSEQ is used in actual clinical settings to guide patient care, not just in trials but in routine treatment decisions for ALL, CLL, MM, MCL, and DLBCL. With MRD status emerging as a critical marker, physicians increasingly rely on these insights for timely interventions, therapy adjustment, and improved outcome prediction.

Deepening Assessment: clonoSEQ's Reach in Novel Therapeutics

The expanding role of clonoSEQ isn’t limited to established treatments. The technology is also informing responses to next-generation therapies—such as CAR T-cell therapies, bispecific antibodies, and other targeted agents—making it an essential part of the evolving therapeutic landscape in hematologic oncology. Clinical trials leverage the assay to measure the depth and durability of remission, contributing to faster, more robust drug development.

Precision and Access: What Sets clonoSEQ Apart?

clonoSEQ is the first and only FDA-cleared in vitro diagnostic (IVD) for detecting and tracking MRD in MM or B-ALL using bone marrow, and in CLL using blood or bone marrow. Its sensitivity allows for detection of one malignant cell among a million healthy cells, supporting standardized monitoring and earlier detection of relapse. Additionally, it is available as a laboratory developed test for DLBCL, MCL, and other lymphoid malignancies, and is covered by Medicare for major blood cancers, facilitating broad clinical access.

Key Takeaway: Momentum Continues for clonoSEQ and Adaptive Biotechnologies

With 89 ASH abstracts, clonoSEQ’s prominence signals the accelerating adoption of MRD assessment as a backbone of blood cancer management and research. As noted by Susan Bobulsky, Adaptive’s Chief Commercial Officer, the data "highlights how integral MRD testing has become in patient care and clinical research across hematologic oncology." As MRD testing evolves, its utility is set to grow across more settings, making it a space for investors, clinicians, and patients to watch closely as Adaptive Biotechnologies moves deeper into precision medicine for hematologic malignancies.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI